One treatment being investigated as an adjuvant for anticancer immunotherapies is the use of molecules that trigger the proteins TLR7 and TLR8. For example, the TLR7 stimulant imiquimod is used for the treatment of skin cancer and metastatic melanoma. However, new research, performed by Isabelle Cremer and colleagues, at INSERM U872, Paris, suggests that such approaches should be developed with caution because stimulation of human lung cancer cells with TLR7 or TLR8 agonists increased tumor cell survival and resistance to chemotherapeutics.
TITLE: Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance
AUTHOR CONTACT:
Isabelle Cremer
INSERM U872, Centre de Recherche des Cordeliers, Paris, France.
Phone: 33.1.44.27.90.83; Fax: 33.1.40510420; E-mail: isabelle.cremer@crc.jussieu.fr .
View this article at: http://www.jci.org/articles/view/36551?key=055913a0375e802e2994
Journal of Clinical Investigation